| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -41,284 | -32,999 | -34,386 | -77,350 |
| Stock-based compensation expense | 6,120 | 6,386 | 7,076 | 14,183 |
| Depreciation expense | 98 | 108 | 120 | 297 |
| Accretion of investment discounts, net | 609 | 1,057 | 1,243 | 3,226 |
| Charge for in-process research and development ('ipr&d') milestones | 4,000 | NaN | NaN | NaN |
| Other non-cash items | -53 | 433 | 0 | -264 |
| Accounts receivable, net | NaN | -44 | 30 | -345 |
| Interest receivable | NaN | -6 | 55 | -73 |
| Prepaid expenses and other current assets | -1,433 | -2,658 | 3,221 | -6,523 |
| Operating lease right-of-use assets | 300 | 295 | 336 | 1,099 |
| Deposits and other assets | NaN | 1,976 | NaN | NaN |
| Other assets | 26 | NaN | 0 | -24 |
| Accounts payable | 10 | 275 | -33 | 338 |
| Accrued expenses | -6,674 | -1,209 | 1,095 | -6,484 |
| Inventory impairment and loss on firm purchase commitments | NaN | NaN | NaN | 0 |
| Operating lease liabilities | -327 | 23 | -27 | -1,158 |
| Net cash used in operating activities | -36,882 | -27,903 | -30,368 | -65,072 |
| Purchases of property and equipment | NaN | 86 | 24 | 28 |
| Milestone payments related to ipr&d | 4,000 | NaN | NaN | NaN |
| Purchases of investments | 19,738 | 30,446 | 58,740 | 142,637 |
| Proceeds from maturities of marketable securities | 60,000 | 60,000 | 64,000 | 122,000 |
| Net cash provided by (used in) investing activities | 36,262 | 29,468 | 5,236 | -20,665 |
| Proceeds from financings, net of issuance costs | NaN | -375 | 191,111 | 65,577 |
| Proceeds from exercise of stock options and rsus vesting | 7,159 | 376 | 2,659 | 1,042 |
| Withholding taxes paid on stock-based awards | 3,942 | 209 | 2,164 | 988 |
| Net cash provided by financing activities | 3,217 | -208 | 191,606 | 65,631 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | -111 | 118 | 151 | 805 |
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | 2,486 | 1,475 | 166,625 | -19,301 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 227,636 | 226,161 | 78,837 | NaN |
| Cash, cash equivalents and restricted cash equivalents, end of period | 230,122 | 227,636 | 226,161 | NaN |
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)